Progression of Coronary Atherosclerosis Is Associated with a Common Genetic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression*

There is a common polymorphism in the promoter sequence of the human stromelysin-1 gene, with one allele having a run of six adenosines (6A) and the other five adenosines (5A). We have previously reported, in a 3-year follow-up study of patients with coronary atherosclerosis, that those patients who are homozygous for the 6A allele show a more rapid progression of the disease. In this study, we have investigated whether the 5A/6A promoter polymorphism plays a role in the regulation of stromelysin-1 gene expression. In transient transfection experiments, a stromelysin-1 promoter construct with 6A at the polymorphic site was found to express less of the chloramphenicol acetyltransferase reporter gene than a construct containing 5A. Electrophoretic mobility shift assay and DNase I footprinting revealed the interaction of one or more nuclear protein(s) with the DNA sequence at the 5A/6A polymorphic site. The binding of one of the nucleoprotein factors was more readily detectable with an oligonucleotide probe corresponding to the 6A allele as compared with a probe corresponding to the 5A allele. Replacing the core binding sequence with a random DNA sequence abolished the interaction between the nuclear protein(s) and the probe and also increased reporter gene expression in transiently transfected cells. Thus, the common 5A/6A polymorphism of the human stromelysin-1 promoter appears to play an important role in regulating stromelysin-1 gene expression and may be involved in the progression of coronary heart disease.

[1]  J. McEwan,et al.  Matrix metalloproteinases and cardiovascular disease. , 1995, Circulation research.

[2]  M. Ferguson,et al.  Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. , 1995, Circulation.

[3]  S. Humphries,et al.  The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM Study , 1995, Thrombosis and Haemostasis.

[4]  W D Wagner,et al.  A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1995, Circulation.

[5]  V. Sheffield,et al.  Night blindness in Sorsby's fundus dystrophy reversed by vitamin A , 1995, Nature Genetics.

[6]  S. Tyagi,et al.  Proteinases and restenosis in the human coronary artery: extracellular matrix production exceeds the expression of proteolytic activity. , 1995, Atherosclerosis.

[7]  P. Libby Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[8]  J. Isner,et al.  Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. , 1995, Circulation.

[9]  K. Imai,et al.  Matrix Metalloproteinase 7 (Matrilysin) from Human Rectal Carcinoma Cells , 1995, The Journal of Biological Chemistry.

[10]  R. Mecham,et al.  Activation of the 92-kDa Gelatinase by Stromelysin and 4-Aminophenylmercuric Acetate , 1995, The Journal of Biological Chemistry.

[11]  A. Hamsten,et al.  Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Henney,et al.  Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. , 1994, British heart journal.

[13]  P. Libby,et al.  Enhanced Expression of Vascular Matrix Metalloproteinases Induced In Vitro by Cytokines and in Regions of Human Atherosclerotic Lesions a , 1994, Annals of the New York Academy of Sciences.

[14]  P. Talmud,et al.  European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[15]  R. Pruett,et al.  Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy , 1994, Nature Genetics.

[16]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[17]  George Bou-Gharios,et al.  Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[18]  S. Quinones,et al.  Promoter elements in the transcriptional activation of the human stromelysin-1 gene by the inflammatory cytokine, interleukin 1. , 1994, Biochemical Journal.

[19]  E. Avvedimento,et al.  A polymorphism (G-->A transition) in the -78 position of the apolipoprotein A-I promoter increases transcription efficiency. , 1994, The Journal of biological chemistry.

[20]  M. Diaz-Meco,et al.  Zeta PKC plays a critical role during stromelysin promoter activation by platelet-derived growth factor through a novel palindromic element. , 1994, The Journal of biological chemistry.

[21]  V. V. van Hinsbergh,et al.  Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. , 1993, The Biochemical journal.

[22]  J. Shafer,et al.  Functional characterization of promoter elements involved in regulation of human B beta-fibrinogen expression. Evidence for binding of novel activator and repressor proteins. , 1993, The Journal of biological chemistry.

[23]  A. Henney,et al.  The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. , 1993, The Journal of biological chemistry.

[24]  Beat Steinmann,et al.  Connective tissue and its heritable disorders —Molecular, genetic and medical aspects , 1993 .

[25]  M. Diaz-Meco,et al.  Protein kinase C-independent expression of stromelysin by platelet-derived growth factor, ras oncogene, and phosphatidylcholine-hydrolyzing phospholipase C. , 1991, The Journal of biological chemistry.

[26]  R. Sturrock,et al.  Antibodies to Proteus in rheumatoid arthritis. , 1991, British journal of rheumatology.

[27]  A. Henney,et al.  Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Giovanna Buttice,et al.  The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin gene , 1991, Nucleic Acids Res..

[29]  L. Poellinger,et al.  High level expression of functional full length and truncated glucocorticoid receptor in Chinese hamster ovary cells. Demonstration of ligand-induced down-regulation of expressed receptor mRNA and protein. , 1991, The Journal of biological chemistry.

[30]  J. Woessner,et al.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[32]  C. Brinckerhoff,et al.  Interleukin-1 or phorbol induction of the stromelysin promoter requires an element that cooperates with AP-1. , 1991, Nucleic acids research.

[33]  L. Matrisian,et al.  TGF-β1 inhibition of transin/stromelysin gene expression is mediated through a fos binding sequence , 1990, Cell.

[34]  L. Matrisian,et al.  Metalloproteinases and their inhibitors in matrix remodeling. , 1990, Trends in genetics : TIG.

[35]  G. V. R. Born,et al.  INFLUENCE OF PLAQUE CONFIGURATION AND STRESS DISTRIBUTION ON FISSURING OF CORONARY ATHEROSCLEROTIC PLAQUES , 1989, The Lancet.

[36]  Y. Otani,et al.  Transcriptional regulation of human stromelysin. , 1989, The Journal of biological chemistry.

[37]  L. Matrisian,et al.  Growth factors regulate transin gene expression by c-fos-dependent and c-fos-independent pathways. , 1988, Science.

[38]  H. Ruley,et al.  Transcription from the stromelysin promoter is induced by interleukin-1 and repressed by dexamethasone. , 1987, The Journal of biological chemistry.

[39]  J. Reynolds,et al.  Current views of collagen degeradation. Progress towards understanding the resorption of connective tissues , 1985 .

[40]  R. Bernlohr,et al.  A new spectrophotometric assay for protein in cell extracts. , 1977, Analytical biochemistry.